Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial

Autor:	Melissa F Djodikromo, Rosella PMG Hermens, Bart JF van den Bemt, Yolba Smit, Tim M Govers, Charlotte L Bekker, Nicole MA Blijlevens
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	Chronic myeloid leukaemia Tyrosine kinase inhibitors Dose reduction Shared decision making Patient-centred care Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Druh dokumentu:	article
ISSN:	1471-2407
DOI:	10.1186/s12885-023-10697-6
Popis:	Abstract Background Dose reduction of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukaemia (CML) with an optimal response to TKIs may support cost-effective medication use by maintaining therapeutic effectiveness while reducing adverse events and medication costs. As the choice for dose reduction depends on patients’ individual needs and preferences, a patient-centred approach is warranted. Therefore, a study to evaluate the effectiveness of patient-guided dose reduction in patients with CML who are in a major or deep molecular response is designed. Methods This study is a prospective, multicentre, single-arm study. 147 patients with CML (aged ≥ 18 years) in chronic phase, who are treated with imatinib, bosutinib, dasatinib, nilotinib or ponatinib, and have reached at least major molecular response (defined as having BCR-ABL levels
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/660c43c24cb144448a2c018c9ee34ecb Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.